This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

By Sriparna Roy (Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a ...

Introduction & Market Context Legend Biotech Corporation (NASDAQ: LEGN) presented its first quarter 2025 financial results and corporate update on May 13, 2025, highlighting the continued commercial ...

Biotechnology encompasses a variety of techniques that employ living cells and molecules, such as enzymes, derived from organisms to produce or alter products and processes. In the plastics sector, ...

Vinay Prasad's appointment as CBER director has caused biotech stocks to fall due to concerns over potential regulatory changes. Prasad's history of criticizing FDA decisions suggests possible ...

Closed-Loop Linear Slide Design with Voice Coil Motor and Linear Encoder The V-308 is built on a closed-loop motorized linear slide, featuring an optical position sensor that delivers sub-nanometer ...

Krystal Biotech reported net product revenue of $88.2 million for VYJUVEK in Q1 2025, representing a 95% increase compared to Q1 2024, but a sequential decline from $91.1 million in Q4 2024. The ...

Krystal Biotech reported net product revenue of $88.2 million for VYJUVEK in Q1 2025, representing a 95% increase compared to Q1 2024, but a sequential decline from $91.1 million in Q4 2024.

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and ...

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.